Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma
European Journal of Haematology · 2026-12 · 117 (6) · 1461-1474
DOI: 10.1111/ejh.70301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 25.08.2026. Verfasst von Mahin Bhatt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, T-Lymphocytes, Antineoplastic Agents, Immunological. Die Arbeit nennt 81 Literaturangaben. Gefördert von: National Institutes of Health, USA, National Institutes of Health.
Abstract (Originalsprache)
Bispecific antibodies have reshaped the therapeutic landscape for relapsed/refractory multiple myeloma (RRMM), complementing proteasome inhibitors, IMiDs, and anti‐CD38 antibodies and competing with BCMA‐directed CAR‐T cells. In this review, we discuss the structure, mechanisms of action, and clinical data for currently approved and emerging T‐cell redirecting antibodies and discuss practical questions around sequencing with CAR‐T therapy, toxicity mitigation, and resistance. Bispecific T‐cell engagers have shown high response rates in early relapse, as well as multidrug‐refractory disease and post‐CAR‐T relapse, but are limited by continuous dosing, infections, hypogammaglobulinemia, cytopenias, cytokine release syndrome (CRS), and neurologic toxicity. We review emerging concepts in resistance like T‐cell exhaustion, antigen loss, soluble BCMA, and extramedullary disease and discuss strategies to enhance efficacy, including combinations with anti‐CD38 antibodies and IMiDs. Bispecific antibodies have become indispensable in relapsed myeloma, and for patients who are ineligible for or relapse after CAR‐T therapy. With multiple clinical trials and new molecules in development, rational sequencing and combination approaches will determine how far their promise translates into durable disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Mahin Bhatt, S Vincent Rajkumar, Shaji Kumar
Förderung
- National Institutes of Health, USA
- National Institutes of Health
Zitieren
APA
Bhatt, M., Rajkumar, S. V., & Kumar, S. (2026). Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma. European Journal of Haematology, 117(6), 1461-1474. https://doi.org/10.1111/ejh.70301
Vancouver
Bhatt M, Rajkumar SV, Kumar S. Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma. European Journal of Haematology. 2026;117(6):1461-1474. doi:10.1111/ejh.70301
BibTeX
@article{Bhatt2026,
author = {Bhatt, Mahin and Rajkumar, S Vincent and Kumar, Shaji},
title = {Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {6},
pages = {1461--1474},
doi = {10.1111/ejh.70301}
}
EUVIMED